The nation of Zimbabwe has declined a significant American health deal valued at $367m (£272m) spanning five years due to Washington's request for sensitive information.
This rejection came to light following a official document from December was disclosed, indicating that Head of State Emmerson Mnangagwa felt the arrangement was "lopsided".
A government spokesperson later clarified that the United States was seeking biological samples for scientific study and commercial gain while was unwilling to guarantee the resulting advantages from any future vaccines.
"We will now turn to the difficult and regrettable process of ending our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had provided more than $1.9bn for health programmes to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged further negotiations to reach a agreement agreeable to both sides so the country's vital HIV programme can continue.
Broader Context
This rejection comes after a comparable case in Kenya, where a court suspended a similar deal with the US after legal challenges were raised about the security of Kenyans' medical information.
Since resuming office last year, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
The agency had managed assistance for the US government, but Trump stated its spending was "wasteful" and his administration was pursuing government-to-government deals to enhance openness and responsibility.
As per statements, Sixteen nations in Africa have to date agreed to these new health pacts, representing over $18.3bn of fresh investment.
Details of the Rejected Deal
The funds for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this partnership would have delivered extraordinary advantages for the people of Zimbabwe, especially the 1.2 million currently receiving HIV treatment through US-supported programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"Zimbabwe was being asked to provide its biological resources and data indefinitely, with no corresponding promise of benefiting from any medical innovations – such as new medicines or tests – that might result from that shared data," his statement read.
"Put simply, our nation would provide the basic resources for medical research with no assurance that the end products would be available to our population should a future health crisis arise."
Sovereignty and Global Health
Mangwana further noted that the US's withdrawal from the global health body and its push of one-on-one health agreements were undermining frameworks previously set up through the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing framework designed to deal with future global health emergencies.
"This framework is designed to guarantee that when a country provides its data, the benefits – including vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the resources to create them."
The government's concerns over the US deal "must not be interpreted as hostility towards the US," he added.
"We are open to further discussions with our US partners on how subsequent collaboration might be arranged in a manner that honours the independence and interests of both nations."
Medical Community Reaction
A leading public health body said it acknowledged the government's concerns, but suggested that negotiations need to persist considering much of the nation's Aids initiatives depended on external financing.
"Where technical issues exist, such as those relating to data governance or implementation frameworks, these can often be addressed via detailed discussion and mutually agreed protections," it commented.
This impasse highlights the complex tensions between receiving vital international aid and safeguarding a country's data in an ever more data-driven world.